Cyrus Harmon - 20 Jan 2026 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Role
Director
Signature
/s/ Shane Kovacs, Attorney-in-Fact
Issuer symbol
OLMA
Transactions as of
20 Jan 2026
Net transactions value
-$268,800
Form type
4
Filing time
21 Jan 2026, 21:00:05 UTC
Previous filing
16 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Harmon Cyrus Director C/O OLEMA PHARMACEUTICALS, INC., 780 BRANNAN ST, SAN FRANCISCO /s/ Shane Kovacs, Attorney-in-Fact 21 Jan 2026 0001831410

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OLMA Common Stock Sale $268,800 -10,000 -1.4% $26.88 727,770 20 Jan 2026 Direct F1
holding OLMA Common Stock 117,028 20 Jan 2026 See Footnote F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 2. The weighted average sale price for the transaction reported was $26.88, and the range of prices were between $26.85 and $26.96. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F2 The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager.